S-nitrosothiol analyzer for the clinical diagnosis of cardiovascular disease mark

Information

  • Research Project
  • 8130794
  • ApplicationId
    8130794
  • Core Project Number
    R44HL095181
  • Full Project Number
    5R44HL095181-03
  • Serial Number
    95181
  • FOA Number
    PA-09-080
  • Sub Project Id
  • Project Start Date
    3/15/2009 - 15 years ago
  • Project End Date
    5/31/2012 - 12 years ago
  • Program Officer Name
    BALDWIN, TIM
  • Budget Start Date
    6/1/2011 - 13 years ago
  • Budget End Date
    5/31/2012 - 12 years ago
  • Fiscal Year
    2011
  • Support Year
    3
  • Suffix
  • Award Notice Date
    7/11/2011 - 12 years ago
Organizations

S-nitrosothiol analyzer for the clinical diagnosis of cardiovascular disease mark

DESCRIPTION (provided by applicant): The goal of this study is to develop a novel electrochemical S-nitrosothiol (RSNO) sensing system with an optimized detection limit and to finalize the specifications required to build a practical RSNO tool for clinical diagnostic applications. RSNO's are a primary carrier and reservoir of NO in vivo and are a potential pre-symptom marker for hypertensive disorders, endothelial dysfunction, cardiovascular risk and inflammation. However, the clinical significance of endogenous RSNO levels cannot be fully realized as a vascular diagnostic tool or biomarker without a quick and convenient assay for RSNO's. Compared to existing RSNO assay techniques, the proposed electrochemical RSNO sensor is highly sensitive and selective, is capable of rapidly measuring RSNO's in blood without separation or pretreatments and is suitable for simple and robust point-of-care use as a clinical diagnostic. A novel catalytic membrane will be prepared by covalently modifying cellulose dialysis membranes with selenocystamine to enhance the sensitivity of the RSNO sensor. The design parameters, including appropriate blood dilution ratios, light protection, temperature control, sensor/reagent stability and the tolerance to varying levels of blood components (e.g. hematocrit/hemoglobin) will be determined in Phase I and will serve as the criteria to build and validate the prototype point-of-care RSNO assay that will be assessed as a biomarker for pulmonary arterial hypertension (PAH) in Phase II. PUBLIC HEALTH RELEVANCE: The goal in this grant is to develop a novel electrochemical S-nitrosothiol (RSNO) sensor with enhanced limit of detection, and to determine the specifications to use this RSNO sensor as the detector to build a practical RSNO analyzer for clinical diagnostic applications, first for trial in pulmonary arterial hypertension (PAH). Currently there is no quick and convenient technique to measure endogenous RSNO concentrations reliably.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    873517
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:873517\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACCORD BIOMATERIALS, INC.
  • Organization Department
  • Organization DUNS
    622586696
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481038802
  • Organization District
    UNITED STATES